Common drugs that increase the risk of Alzheimer's disease

A new study suggests that anticholinergic drugs may increase the risk of accelerated cognitive decline. Especially in the elderly who are at high risk of developing Alzheimer’s disease.

Depression, urinary incontinence, seasonal allergies: the most prescribed drugs are most at risk

Anticholinergic drugs block the action of acetylcholine, a chemical messenger that controls a range of automatic bodily functions and plays a vital role in memory and attention. Doctors prescribe these drugs for various conditions. These include urinary incontinence, overactive bladder, chronic obstructive pulmonary disease (COPD), seasonal allergies and depression.

However, over the past decade, growing evidence many indicate that anticholinergics may increase the risk of dementia in the elderly. Researchers at the University of California, San Diego have now linked anticholinergics to mild cognitive impairment, which can lead to dementia, including Alzheimer’s disease.

The increased risk was particularly pronounced in people who had biomarkers of Alzheimer’s disease in their cerebrospinal fluid and in those who had an increased genetic risk of developing the disease. This interaction between anticholinergic drugs and biomarkers of Alzheimer’s risk is doubly effective. In the first case, biomarkers for Alzheimer’s disease indicate that the degeneration begins in a small region of the brain called the basal forebrain, which produces acetylcholine. Then, in the second case, anticholinergic drugs further deplete the brain’s acetylcholine stores. This combined effect has a very significant impact on a person’s thinking and memory.

An increase of 47% risk of cognitive impairment

The study focused on 688 people who participated in the Alzheimer’s disease neuroimaging initiative. The participants had an average age of 74 years, and none showed signs of cognitive or memory problems at the start of the study. A third of them were taking at least one type of medication, with an average of 4.7 anticholinergic drugs per person. There were no differences in genetic risk factors between people taking anticholinergics and those not taking them.

However, depressive symptoms, total number of medications and heart problems were greater in people taking anticholinergics. Therefore, these variables were taken into account in all subsequent analyses. From the start of the study, participants took annual cognitive tests for a period of up to 10 years.

Among those taking at least one anticholinergic, there was an overall increase in 29 % risk of mild cognitive impairment compared to those taking none. Those who took these drugs and were genetically at risk of developing Alzheimer’s disease were more than 2.5 times more likely to develop mild cognitive impairment than those who did not take the drugs and were not genetically at risk . Participants who had Alzheimer’s biomarkers in their cerebrospinal fluid at the start of the study and who were taking anticholinergics were almost 5 times more likely to show signs of mild cognitive impairment.


The study results are published in the journal Neurology. /02/WNL.0000000000010643

Presse Santé strives to transmit health knowledge in a language accessible to all. In NO CASE, the information given can replace the advice of a health professional.

Do you like our content?

Receive our latest publications every day for free and directly in your mailbox


antidepressants Alzheimer’s disease drugs drugs related to Alzheimer’s disease

Related Articles

Back to top button